Current Research and Trends
Diagnosis
Point-of-care testing.
Anderson, D. A., Crowe, S. M., & Garcia, M. (2011). Curr HIV/AIDS Rep, 8(1), 31-37.
Performance of HIV-1 DNA or HIV-1 RNA tests for early diagnosis of perinatal HIV-1 infection during anti-retroviral prophylaxis.
Burgard, M., et al. (2012). J Pediatr, 160(1), 60-66.
Identifying the early post-HIV antibody seroconversion period.
Hecht, F. M., et al. (2011). J Infect Dis, 204(4), 526-533.
Establishing diagnostic cut-off criteria for the COBAS AmpliPrep/COBAS TaqMan HIV-1 Qualitative test through validation against the Amplicor DNA test v1.5 for infant diagnosis using dried blood spots.
Maritz, J., Preiser, W., & van Zyl, G. U. (2012). J Clin Virol, 53(2), 106-109.
Anderson, D. A., Crowe, S. M., & Garcia, M. (2011). Curr HIV/AIDS Rep, 8(1), 31-37.
Performance of HIV-1 DNA or HIV-1 RNA tests for early diagnosis of perinatal HIV-1 infection during anti-retroviral prophylaxis.
Burgard, M., et al. (2012). J Pediatr, 160(1), 60-66.
Identifying the early post-HIV antibody seroconversion period.
Hecht, F. M., et al. (2011). J Infect Dis, 204(4), 526-533.
Establishing diagnostic cut-off criteria for the COBAS AmpliPrep/COBAS TaqMan HIV-1 Qualitative test through validation against the Amplicor DNA test v1.5 for infant diagnosis using dried blood spots.
Maritz, J., Preiser, W., & van Zyl, G. U. (2012). J Clin Virol, 53(2), 106-109.
Treatment and Therapy
Safety and exposure of once-daily ritonavir-boosted atazanavir in HIV-infected pregnant women. Conradie, F., et al. (2011). HIV Med, 12(9), 570-579. doi:10.1111/j.1468-1293.2011.00927.x
CD4+ cell count and risk for antiretroviral drug resistance among women unsing peripartum nevirapine for perinatal HIV prevention.
Dorton, B. J., et al. (2011). BJOG, 118(4), 495-499. doi:10.1111/j.1471-0528.2010.02835.x
Infant safety during and after maternal valacyclovir therapy in conjunction with antiretroviral HV-1 prophylaxis in a randomized clinical trial.
Drake, A. L., et al. (2012). PLoS One, 7(4), e34635.
Valacyclovir suppressive therapy reduces plasma and breast milk HIV-1 RNA levels during pregnancy and postpartum: a randomized trial.
Drake, A. L., et al. (2012). J Infect Dis, 205(3), 366-375.
Safety and pharmacokinetics of nelfinavir during the second and third trimesters of pregnancy and postpartum.
Fang, A., et al. (2012). HIV Clin Trials, 13(1), 46-59.
Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial.
Gibb, D. M., et al. (2012). PLoS Med, 9(5), e1001217.
Disparities in outcomes for African American and Latino subjects in the Flexible Initial Retrovirus Suppressive Therapies (FIRST) trial.
Giordano, T. P., et al. (2010). AIDS Patient Care and STDs, 24(5), 287-295.
HIV medications: an update and review of metabolic complications.
Hester, E. K. (2012). Nutr Clin Pract, 27(1), 51-64.
A high-affinity inhibitor of human CD59 enhances complement-mediated virolysis of HIV-1: implications for treatment of HIV-1/AIDS.
Hu, W., et al. (2010). J Immunol, 184(1), 259-268.
Effects of infant massage on HIV-infected mothers and their infants.
Oswalt, K., & Biasini, F. (2011). J Spec Pediatr Nurs, 16(3), 169-178. doi:10.1111/j.1744-6155.2011.00291.x
Antiretroviral treatment for children with peripartum nevirapine exposure.
Palumbo, P., et al. (2010). N Engl J Med, 363(16), 1510-1520.
CD4+ cell count and risk for antiretroviral drug resistance among women unsing peripartum nevirapine for perinatal HIV prevention.
Dorton, B. J., et al. (2011). BJOG, 118(4), 495-499. doi:10.1111/j.1471-0528.2010.02835.x
Infant safety during and after maternal valacyclovir therapy in conjunction with antiretroviral HV-1 prophylaxis in a randomized clinical trial.
Drake, A. L., et al. (2012). PLoS One, 7(4), e34635.
Valacyclovir suppressive therapy reduces plasma and breast milk HIV-1 RNA levels during pregnancy and postpartum: a randomized trial.
Drake, A. L., et al. (2012). J Infect Dis, 205(3), 366-375.
Safety and pharmacokinetics of nelfinavir during the second and third trimesters of pregnancy and postpartum.
Fang, A., et al. (2012). HIV Clin Trials, 13(1), 46-59.
Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial.
Gibb, D. M., et al. (2012). PLoS Med, 9(5), e1001217.
Disparities in outcomes for African American and Latino subjects in the Flexible Initial Retrovirus Suppressive Therapies (FIRST) trial.
Giordano, T. P., et al. (2010). AIDS Patient Care and STDs, 24(5), 287-295.
HIV medications: an update and review of metabolic complications.
Hester, E. K. (2012). Nutr Clin Pract, 27(1), 51-64.
A high-affinity inhibitor of human CD59 enhances complement-mediated virolysis of HIV-1: implications for treatment of HIV-1/AIDS.
Hu, W., et al. (2010). J Immunol, 184(1), 259-268.
Effects of infant massage on HIV-infected mothers and their infants.
Oswalt, K., & Biasini, F. (2011). J Spec Pediatr Nurs, 16(3), 169-178. doi:10.1111/j.1744-6155.2011.00291.x
Antiretroviral treatment for children with peripartum nevirapine exposure.
Palumbo, P., et al. (2010). N Engl J Med, 363(16), 1510-1520.
Trends and Current Knowledge
Acquiring human immunodeficiency virus during pregnancy and mother-to-child transmission in New York: 2002-2006.
Birkhead, G. S., et al. (2010). Obstet Gynecol, 1247-1255.
Stress biomarkers as outcomes for HIV+ prevention: participation, feasibility and findings among HIV+ Latina and African American mothers.
Glover, D. A., et al. (2010). AIDS and Behavior, 14(2), 339-350.
Infant feeding practices at routine PMTCT sites, South Africa: results of a prospective observational study amongst HIV exposed and unexposed infants - birth to 9 months.
Goga, A. E., et al. (2012). Int Breastfeed, 7, 4.
What have we learned from sexually transmitted infection research in sub-Saharan Africa?
Mabey, D., Ndowa, F., & Latif, A. (2010). Sex Transm Infect, 86(7), 488-492.
HIV/AIDS in women: An expanding epidemic.
Quinn, T. C., & Overbaugh, J. (2005). Science, 308(5728), 1582-1583.
Birkhead, G. S., et al. (2010). Obstet Gynecol, 1247-1255.
Stress biomarkers as outcomes for HIV+ prevention: participation, feasibility and findings among HIV+ Latina and African American mothers.
Glover, D. A., et al. (2010). AIDS and Behavior, 14(2), 339-350.
Infant feeding practices at routine PMTCT sites, South Africa: results of a prospective observational study amongst HIV exposed and unexposed infants - birth to 9 months.
Goga, A. E., et al. (2012). Int Breastfeed, 7, 4.
What have we learned from sexually transmitted infection research in sub-Saharan Africa?
Mabey, D., Ndowa, F., & Latif, A. (2010). Sex Transm Infect, 86(7), 488-492.
HIV/AIDS in women: An expanding epidemic.
Quinn, T. C., & Overbaugh, J. (2005). Science, 308(5728), 1582-1583.
Updated 2012 by Peace Ossom